SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 
SpaceX Starship Explodes in Texas During Test, Citing Nitrogen Tank Failure 
Asian Markets Rally as Oil Prices Tumble and Middle East Peace Hopes Emerge 
Democratic Attorneys General Sue Trump Administration Over CDC Childhood Vaccine Schedule Changes 
Sanofi Gains China Approval for Myqorzo and Redemplo, Strengthening Rare Disease Portfolio 
Nintendo Switch 2 Production Cut as Holiday Sales Miss Targets 
Air Canada Express Crash at LaGuardia: Controller Distracted by Prior Emergency 
Is space worth the cost? Accounting experts say its value can’t be found in spreadsheets 
Australia's Inflation Eases in February but Core Pressures Persist 
Middle East War Rattles Global Markets as Oil Tops $100 and Dollar Surges 
Sonova Shares Slip as Hearing Aid Giant Lowers Growth Outlook and Plans Sennheiser Exit 
Tabletop particle accelerator could transform medicine and materials science 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Novo Nordisk Shares Tumble After CagriSema Misses Key Trial Endpoint 
Asian Currencies Hold Steady as Dollar Stays Firm Amid Middle East Uncertainty 
A South Korean research team has developed a strip-type urine test that successfully diagnoses prostate and pancreatic cancer on-site by amplifying the optical signal of the metabolome in urine.
The joint research team is from the Korea Institute of Materials Science, Pohang University of Science and Technology, and Kyung Hee University
The surface-enhanced Raman scattering sensor that they developed can amplify the optical signal of the metabolome in urine by more than 1 billion times by forming a coral reef-shaped plasmonic nanomaterial on top of porous paper material.
A light irradiation after a 10-microliter urine droplet amplified signal of cancer metabolome on the sensor’s surface without the need to go through a separate analysis process,.
The application of an artificial intelligence-based analytical method for the spectrum signal generated through the irradiation of light into the urine can identify people with prostate cancer and pancreatic cancer with an accuracy of up to 99 percent.
